Ipamorelin & CJC-1295 Mix
(Mix of Ipamorelin & CJC-1295)
5 mg Ipamorelin & 5 mg CJC-1295 in each vial
10 vials x 10 mg
Ipamorelin is a penta-peptide hormone (Aib-His-D-2-Nal-D-Phe-Lys-NH2), a growth hormone secretagogue and a small molecule of ghrelin mimetic developed by Novo Nordisk. Ipamorelin belongs to the most recent generation of GHRPs and causes significant release of growth hormone. Similar to GHRP-2, it suppresses somatostatin and increases the stimulation and release of Growth Hormone (GH) from the anterior pituitary. Currently, these are few clinical trials involving Ipamorelin, which were first being studied in the 90s. Ipamorelin significantly increases plasma growth hormone (GH) levels in both animals. In addition, Ipamorelin stimulates body weight gain in animals. Like GHRP-6, Ipamorelin does not affect prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH) levels.
CJC-1295 is a tetrasubstituted 30-amino acid peptide hormone, primarily functioning as a growth hormone releasing hormone (GHRP) analog. It has D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively.
Ipamorelin & CJC-1295 are sterile, non-pyrogenic, white lyophilized powder intended for subcutaneous or intramuscular injection, after reconstitution with sterile Water for Injection.